drugset / Trial / NCT02470650
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study is to know the efficiency (costeffectiveness) at 48 weeks of initiation of antiretroviral treatment. three strategies of treatment.
Timeline
- Start
- 2015-06
- Primary completion
- 2017-07
- Completion
- 2017-10
Outcome
Outcome not reported
Stopped (Enrollment): “No participants enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Darunavir | Small molecule | 800 mg | — |
| Comparator | Lamivudine | Other / unclassified | 300 mg | — |
| Comparator | Rilpivirine | Small molecule | 25 mg | — |
| Comparator | Ritonavir | Other / unclassified | 100 mg | — |
| Comparator | abacavir/lamivudine | Unknown | 300 mg | — |
| Comparator | abacavir/lamivudine | Unknown | 600 mg | — |
| Subject | elvitegravir/cobicistat/emtricitabine/tenofovir | Unknown | 150 mg | — |
| Subject | elvitegravir/cobicistat/emtricitabine/tenofovir | Unknown | 200 mg | — |
| Subject | elvitegravir/cobicistat/emtricitabine/tenofovir | Unknown | 245 mg | — |